Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.60 |
| ▸ | TSHR | P16473 | 6/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8459523 | 0.89 | TSHR (0.60) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL2662863 | 0.86 | LMNA (0.60) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL738726 | 0.86 | HSD17B10 (0.55) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL6853371 | 0.83 | HSD17B10 (0.60) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL4062679 | 0.83 | LMNA (0.58) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL69259 | 0.78 | HSD17B10 (0.80) | HSD17B10TSHRHPGDALDH1A1CYP3A4 | |
| SCHEMBL8261003 | 0.78 | CD44 (0.58) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL6841859 | 0.78 | LMNA (0.52) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL13855825 | 0.78 | HSD17B10 (0.52) | HSD17B10TSHRHPGDLMNAALDH1A1 | |
| SCHEMBL16250473 | 0.77 | HSD17B10 (0.46) | HSD17B10TSHRHPGDLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4429168-A | PREFERENTIAL COMPLEXING WITH A METAL HALIDE SALT | KOPPERS COMPANY, INC. (US) | 1984-01-31 | — | — | US | claimed |
| EP-4085059-B1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE HK LTD (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2023-04-20 | — | — | US | disclosed |
| US-11555012-B2 | ACLY inhibitors and uses thereof | Nimbus Artemis, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021138694-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2021-07-08 | — | — | WO | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2020-02-20 | — | — | US | disclosed |
| US-10383331-B2 | Liquid antimicrobial comprising a water-soluble polymer and a water-soluble antimicrobial agent | FANTEX LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-7399890-B2 | Method for the hydrodehalogenation of halogenated meta-cresols | LANXESS DEUTSCHLAND GMBH (DE) | 2008-07-15 | — | — | US | disclosed |
| WO-2007104944-A1 | PYRROLOPYRIMIDINE DERIVATIVES USED AS HSP90 INHIBITORS | VERNALIS (R & D) LTD. (GB) | 2007-09-20 | — | — | WO | disclosed |
| US-20070149829-A1 | Method for the hydrodehalogenation of halogenated meta-cresols | LANXESS DEUTSCHLAND GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
| EP-0443533-B1 | Positive photoresist composition | FUJI PHOTO FILM CO LTD (JP) | 1998-09-30 | — | — | EP | disclosed |
| EP-0443533-A2 | Positive photoresist composition | FUJI PHOTO FILM CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4588835-A | Process for preparing alkoxyphenols | OTSUKA KAGAKU YAKUHIN KABUSHIKI KAISHA (JP) | 1986-05-13 | — | — | US | disclosed |
| US-4489210-A | PREVENTION OF THE FORMATION OF BUBBLES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-12-18 | — | — | US | disclosed |
| US-4469900-A | PREFERENTIAL COMPLEXING WITH CALCIUM BROMIDE | KOPPERS COMPANY, INC. (US) | 1984-09-04 | — | — | US | disclosed |
| US-4429168-A | PREFERENTIAL COMPLEXING WITH A METAL HALIDE SALT | KOPPERS COMPANY, INC. (US) | 1984-01-31 | — | — | US | disclosed |
| US-4219547-A | Phosphoroimidophenyl insecticides | STAUFFER CHEMICAL COMPANY (US) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149829-A1 | Method for the hydrodehalogenation of halogenated meta-cresols | C5, C9, C1S | HSD17B10 626/4885TSHR 853/4885HPGD 1413/4885 |
| US-20230121233-A1 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | BAX, PDCD1, PDCD4 | HSD17B10 948/4885TSHR 3786/4885HPGD 176/4885 |
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | HSD17B10 392/4885TSHR 4803/4885HPGD 1212/4885 |
| US-11555012-B2 | ACLY inhibitors and uses thereof | ACLY, ATP5ME, ATP5MG | HSD17B10 392/4885TSHR 4803/4885HPGD 1212/4885 |
| US-20200055845-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | HSD17B10 3891/4885TSHR 4206/4885HPGD 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.